月別アーカイブ: 2014年6月

Paseo Oaks Pharmacy Compounds Unavailable Medication

THOUSAND OAKS, Calif., June 30, 2014 /PRNewswire/ – Paseo Oaks Compounding Pharmacy compounds unavailable medications to benefit their patients. Medications can become unavailable or hard to locate due to manufacturing issues, declining profits or the introduction of new drugs. Medications may also be discontinued from the mass-produced drug market due to decreased demand, a change in formulation or altered doses or dosage forms. Drugs that have been withdrawn due to potential health risks may not be eligible for pharmacy compounding services because of safety concerns.

Paseo Oaks Pharmacy is a licensed compounding pharmacy with a commitment to providing its patients with the treatments they need, and they offer Calabasas compounding pharmacy delivery services for area patients. They offer hormone therapies for men and women, provide postpartum care, develop treatments for fibromyalgia, chronic fatigue syndrome, hospice and palliative care, adjust dosages for patients with special needs, and create child-friendly flavors for pediatric medications. Dermatological, podiatry and veterinary medications are also available. Their team can deliver prescriptions to patients throughout the Paseo Oaks and Los Angeles areas, and a variety of payment options are available for patient convenience. Agoura Hills compounding pharmacy delivery services and Westlake Village compounding pharmacy delivery services are also available.

Pharmacy compounding is a specialty service that uses pharmaceutical-grade ingredients to provide precise formulations according to a licensed doctor’s prescription. It allows patients to enjoy more personalized health care that can be fully customized to meet their individual needs. Professional pharmacists at Paseo Oaks Pharmacy are able to use the active pharmaceutical ingredient for discontinued medications and compound them into the most appropriate dose and dosage form for each patient.  Visit http://www.paseorx.com for more information.

Additional adjustments to medications can also be made. The skilled team at Paseo Oaks Pharmacy can eliminate common additives and allergens, including dyes, gluten, preservatives, sugar and alcohol. They use only pharmaceutical-grade FDA-approved ingredients, follow all current guidelines and are licensed to practice pharmacy compounding. The latest technology and equipment are used, and their advanced records system can significantly reduce the risk of side effects, drug interactions and other unwanted problems. 

While compounding is an excellent option for those whose medications have been discontinued, it can also be a good choice for patients who simply need more customized treatment options due to special physical or personal needs.

Website: http://www.paseorx.com

Press Release by http://www.avitalweb.com

Source Article from http://ca.finance.yahoo.com/news/paseo-oaks-pharmacy-compounds-unavailable-140000614.html
Paseo Oaks Pharmacy Compounds Unavailable Medication
http://ca.finance.yahoo.com/news/paseo-oaks-pharmacy-compounds-unavailable-140000614.html
http://news.search.yahoo.com/news/rss?p=pharmacy
pharmacy – Yahoo News Search Results
pharmacy – Yahoo News Search Results





Recro Pharma Added to Russell Microcap(R) Index

MALVERN, Pa., June 30, 2014 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced that it was added to the Russell Microcap(R) Index following market close on June 27, 2014.

The Russell Microcap(R) Index measures the performance of the microcap segment of the U.S. equity market. Microcap stocks make up less than 3 percent of the U.S. equity market (by market cap) and consist of the smallest 1,000 securities in the small-cap Russell 2000(R) Index, plus the next 1,000 smallest eligible securities by market cap.

According to information published by Russell, annual reconstitution of Russell indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000(R) Index and Russell Microcap(R). Membership in the Russell Microcap(R) Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. According to Russell, approximately $5.2 trillion in assets are benchmarked to the Russell Indexes. Russell calculates approximately 700,000 benchmarks daily covering approximately 98 percent of the investable market globally, 80 countries and more than 10,000 securities. These investment tools originated from Russell’s multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

About Recro Pharma, Inc.

Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. Recro Pharma’s lead product candidate, Dex-IN, is a proprietary intranasal formulation of dexmedetomidine and has completed a placebo controlled, proof of concept Phase Ib trial demonstrating effective pain relief. As Recro Pharma’s product candidates are not in the opioid class of drugs, the company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress while maintaining analgesic effect. If approved, Dex-IN would be the first and only approved acute pain drug in its class of drugs.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Recro Pharma’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Recro Pharma or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Recro Pharma as of the date of this press release and are subject to a number of risks, uncertainties, and other factors that could cause Recro Pharma’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Recro Pharma assumes no obligation to update any such forward-looking statements. Factors that could cause Recro Pharma’s actual results to materially differ from those expressed in the forward-looking statements set forth in this press release include, without limitation: the results and timing of the company’s Phase IIb clinical trial of Dex-IN; the ability to obtain and maintain regulatory approval of product candidates, and the labeling under any such approval; regulatory developments in the United States and foreign countries; the company’s ability to raise future financing for continued development; the performance of third-party suppliers and manufacturers; the company’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection; the successful commercialization of the company’s product candidates; and the successful implementation of the company’s strategy. In addition, the forward-looking statements in this press release should be considered together with the risks and uncertainties that may affect Recro Pharma’s business and future results included in Recro Pharma’s filings with the Securities and Exchange Commission at www.sec.gov.

Source Article from http://finance.yahoo.com/news/recro-pharma-added-russell-microcap-110000113.html
Recro Pharma Added to Russell Microcap(R) Index
http://finance.yahoo.com/news/recro-pharma-added-russell-microcap-110000113.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results



Change of number of shares and votes in Moberg Pharma

STOCKHOLM–(BUSINESS WIRE)–

Regulatory News:

The number of shares and votes in Moberg Pharma AB (publ) (MOB.ST) has
increased by 2,068,965 to 13,962,537 during June 2014. Therefore, there
are in total 13,962,537 shares and votes in the company as of June 30th,
2014.

The increase is a result of a directed share issue of 2,068,965 shares
to a limited group of Swedish and international institutional qualified
investors, which was resolved by the board on May 27, 2014 under an
authorization from the annual general meeting May 13 2014. The share
issue was completed in order for Moberg Pharma to increase its financial
flexibility relating to potential acquisition opportunities as well as
preparations for licensing and development of product candidates in
clinical phase.

About this information

Moberg Pharma discloses this information pursuant to the Swedish
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08.30 am (CET) on June
30th, 2014.

About Moberg Pharma

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical
company with a direct sales and marketing organization in the U.S. and
an extensive distributor network in more than 40 countries. The
company’s OTC portfolio includes the brands Kerasal®, Jointflex®,
Kerasal Nail™, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail™ (Nalox™
in certain ex-U.S. markets) is the leading product for the treatment of
nail disorders in the U.S. and Nordic market. The current portfolio will
be supplemented by the acquisition and in-licensing of additional
products as well as product development with a focus on innovative drug
delivery of proven compounds. Moberg Pharma has offices in Stockholm and
New Jersey and the company’s shares (MOB.ST) are listed on the Small
Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further
information, please visit: www.mobergpharma.com.

This information was brought to you by Cision http://news.cision.com

Source Article from http://finance.yahoo.com/news/change-number-shares-votes-moberg-064700941.html
Change of number of shares and votes in Moberg Pharma
http://finance.yahoo.com/news/change-number-shares-votes-moberg-064700941.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results